Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

14.13USD
2:12am IST
Change (% chg)

$0.09 (+0.64%)
Prev Close
$14.04
Open
$14.18
Day's High
$14.46
Day's Low
$13.80
Volume
27,993
Avg. Vol
45,457
52-wk High
$27.77
52-wk Low
$12.04

Chart for

About

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement... (more)

Overall

Beta: --
Market Cap(Mil.): $326.48
Shares Outstanding(Mil.): 22.61
Dividend: --
Yield (%): --

Financials

BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share

* Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update

10 Nov 2017

BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million

* Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2A6uuro) Further company coverage:

02 Nov 2017

BRIEF-Ra Pharmaceuticals reports Q2 loss per share $0.56

* Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

10 Aug 2017

BRIEF-RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

* RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

31 Jul 2017

BRIEF-Ra Pharmaceuticals announces data from phase 2 clinical trial of RA101495

* Ra Pharmaceuticals announces initial data from phase 2 clinical trial of RA101495 in Pnh

27 Jun 2017

Earnings vs. Estimates